Date lodged: 21 December 2016
To ask the Scottish Government what analysis it has carried out of the use of the drug, Ibrutinib, as a second-line therapy treatment for chronic lymphocytic leukaemia.
Answered by: Shona Robison 17 January 2017
In Scotland we have a clear route for new drugs to be appraised through the long standing Scottish Medicines Consortium (SMC).
SMC will consider a resubmission for the use of ibrutinib (Imbruvica®) in adult patients with chronic lymphocytic leukaemia (without genetic changes known as 17p deletion or TP53 mutation) who have received at least one prior therapy and for whom fludarabine-based regimens are inappropriate at their meeting on 7 March 2017 and expect to publish their advice on 10 April 2017.